Pediatric attention-deficit/hyperactivity disorder (ADHD) is a common childhood condition that can continue through adolescence and into adulthood. Despite a number of available—and largely efficacious—pharmacological treatments, opportunity exists for emerging agents that offer improvements in efficacy(including alleviating secondary symptom domains, such as executive functioning) and in safety and tolerability, most notably in terms of the risk for abuse and dependence. The high percentage of patients with inadequate progress in controlling ADHD symptoms, coupled with the need for better maintenance over the long term and other areas requiring considerable advancement, poses a large unmet need and ample commercial opportunity for a new drug to improve pediatric ADHD treatment.
QUESTIONS ANSWERED
PRODUCT DESCRIPTION
Unmet Need provides quantitative insight into U.S. and European physician perceptions of key treatment drivers and goals and the current level of unmet need for a specific disease. Commercial opportunities are analyzed, and the extent to which emerging therapies may capitalize on these opportunities is evaluated.
Markets covered: United States, United Kingdom, France, Germany.
Primary research: Survey of 60 psychiatrists in the United States and 30 psychiatrists in Europe.
Key companies: Eli Lilly, Janssen, Novartis, Shire.
Key drugs: Vyvanse/Elvanse, Concerta, Strattera, Intuniv.
Key metrics included: